Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis considers bid for Berna Biotech

Novartis considers bid for Berna Biotech

20th December 2005

Novartis has announced that it will “explore the benefits” of acquiring the Swiss vaccines company Berna Biotech.

The company said that it is looking at whether Berna could be combined with Chiron, a US vaccines company that Novartis is currently in the process of acquiring.

“The combination of Berna and Chiron offers complementary geographic coverage and product ranges as well as access to the attractive proprietary technology platforms of Berna,” said Novartis in a statement.

Berna markets its core vaccine products in the field of hepatitis B/pediatric, respiratory and travel vaccines and has a broad development pipeline.

Crucell, a Dutch biotechnology company, announced on December 15th an offer to acquire Berna through an all-share exchange offer. In order to prepare a potential competing cash offer, Novartis has requested from and has been granted by Berna the opportunity to perform a due diligence investigation.

However, Novartis stressed that no decision had been reached on whether to make an offer for the firm.

track© Adfero Ltd

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.